Companies › Jubilant Therapeutics India
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JBI-778 Selective PRMT5 inhibitor | PRMT5 | Phase 1 | NSCLC Patients With EGFR Activating Mutation | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07755397 | JBI-778 | Phase 1 | NSCLC Patients With EGFR Activating Mutation | Oncology | Mar 2028 |
Bristol-Myers Squibb Tango Therapeutics Bayer IDEAYA Biosciences Amgen Jiangsu Simcere Pharmaceutical AstraZeneca PharmaEngine Servier Bio-Innovation
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.